Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

<ul><li>SCLX is filling a much-needed area of the health care sector, that of developing non-opioid pain relief products.</li><li> The company already has commercialized products that are proven to improve patients' lives.</li><li> The company announced 3Q2024 earnings that exceeded expectations and continues to look to grow revenues and its portfolio.</li></ul>

SCLX is filling a much-needed area of the health care sector, that of developing non-opioid pain relief products. The company already has commercialized products that are proven to improve patients' lives. The company announced 3Q2024 earnings that exceeded expectations and continues to look to grow revenues and its portfolio.

<ul><li>SCLX is filling a much-needed area of the health care sector, that of developing non-opioid pain relief products.</li><li> The company already has commercialized products that are proven to improve patients' lives.</li><li> The company announced a deal with a developer of a Phase 2 drug with a large market potential to be the exclusive developer and have the right to commercialize the treatment targeting obesity and Alzheimer's disease.</li></ul>

SCLX is filling a much-needed area of the health care sector, that of developing non-opioid pain relief products. The company already has commercialized products that are proven to improve patients' lives. The company announced a deal with a developer of a Phase 2 drug with a large market potential to be the exclusive developer and have the right to commercialize the treatment targeting obesity and Alzheimer's disease.

<ul><li>SCLX is filling a much-needed area of the health care sector, that of developing non-opioid pain relief products.</li><li> The company already has commercialized products that are proven to improve patients' lives.</li><li> The company announced a financing deal that helps to pay off debt and adds cash at good terms.</li></ul>

SCLX is filling a much-needed area of the health care sector, that of developing non-opioid pain relief products. The company already has commercialized products that are proven to improve patients' lives. The company announced a financing deal that helps to pay off debt and adds cash at good terms.

SCLX:  Financing Deal Puts Company in Good Shape

<ul><li>SCLX is filling a much-needed area of the health care sector, that of developing non-opioid pain relief products.</li><li> The company already has commercialized products that are proven to improve patients' lives.</li><li> The company announced a merger between a SPAC and a Scilex subsidiary that is developing a non-opioid novel injectable corticosteroid, which will set up a spinoff of the combined entity in early 2025.</li></ul>

SCLX is filling a much-needed area of the health care sector, that of developing non-opioid pain relief products. The company already has commercialized products that are proven to improve patients' lives. The company announced a merger between a SPAC and a Scilex subsidiary that is developing a non-opioid novel injectable corticosteroid, which will set up a spinoff of the combined entity in early 2025.

<ul><li>SCLX is filling a much-needed area of the health care sector, that of developing non-opioid pain relief products.</li><li> The company already has commercialized products that are proven to improve patients' lives.</li><li> The company released its 2Q2024 results that showed revenues that bested estimates as sales of its primary products showed robust growth, while adding another product to its mix.</li></ul>

SCLX is filling a much-needed area of the health care sector, that of developing non-opioid pain relief products. The company already has commercialized products that are proven to improve patients' lives. The company released its 2Q2024 results that showed revenues that bested estimates as sales of its primary products showed robust growth, while adding another product to its mix.

Singapore

Scilex Holding Company operates as a holding company. The Company, through its subsidiaries, focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Scilex Holding serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Scilex Holding (SCLX US)

SCLX: 3Q Earnings Beat Estimates

SCLX is filling a much-needed area of the health care sector, that of developing non-opioid pain relief products. The company already has...

Zacks Small Cap Research

SCLX: Deal Brings Huge Potential

SCLX is filling a much-needed area of the health care sector, that of developing non-opioid pain relief products. The company already has...

Zacks Small Cap Research

SCLX: Financing Deal Puts Company in Good Shape

SCLX is filling a much-needed area of the health care sector, that of developing non-opioid pain relief products. The company already has...

Zacks Small Cap Research

SCLX: Company Sets up Spinoff

SCLX is filling a much-needed area of the health care sector, that of developing non-opioid pain relief products. The company already has...

Zacks Small Cap Research

SCLX: Revenues Beat Estimates in 2Q

SCLX is filling a much-needed area of the health care sector, that of developing non-opioid pain relief products. The company already has...

Zacks Small Cap Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)